Skip to main content

Table 1 Unit cost and health-utility values used for the economic analysis

From: Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

Category Tariff Origin
Costs   
  Gemcitabine €0.24/mg National reimbursement price [21]
  Erlotinib 30-day supply (150 mg) €2174.70 National reimbursement price [21]
  Pemetrexed €2.45/mg National reimbursement price [21]
  GCS-F €185.80/inj National reimbursement price [21]
  Epoetin €221.2/inj National reimbursement price [21]
  DRG for transfusion €697.10 DRG 11th edition [22]
DRG for outpatient drug administration €400.70 DRG 11th edition [22]
  Palliative care (per month) €2324 [€1627–€3021] Chouaïd [23]
Health-utility values   
Maintenance therapy   
  Observation 0.693 [0.46–0.88] Nafees et al. [24]
  IV chemotherapy (gemcitabine) 0.653 [0.26–0.78] Nafees et al. [24]
  Oral chemotherapy (erlotinib) 0.673 [0.27–0.80] Nafees et al. [24]
Second-line therapy   
IV chemotherapy (pemetrexed) 0.653 [0.26–0.78] Nafees et al. [24]
Palliative care 0.473 [0.19–0.56] Nafees et al. [24]
Death 0  
  1. Abbreviation: DRG diagnosis-related group.